A Phase I, Open Label, Single-Dose Study to Evaluate the Pharmacokinetics of Vi-0521 in Subjects With Hepatic Impairment and In Healthy Control Subjects.

Trial Profile

A Phase I, Open Label, Single-Dose Study to Evaluate the Pharmacokinetics of Vi-0521 in Subjects With Hepatic Impairment and In Healthy Control Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors VIVUS
  • Most Recent Events

    • 04 Dec 2009 Planned number of patients changed from 24 to 18 as reported by ClinicalTrials.gov.
    • 04 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Planned end date (Jul 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top